Health Notices




16 OCTOBER 2008 NEW ZEALAND GAZETTE, No. 159 4181

Health

Medicines Act 1981

Corrigendum—Classification of Medicines

In the notice published in the New Zealand Gazette, 2 October 2008, No. 152, page 4029, the pharmacy-only entry for iron should read:

Iron; for oral use either in medicines containing more than 24 milligrams per recommended daily dose or in medicines containing more than 5 milligrams per dose unit and more than 750 milligrams of iron per pack; except in parenteral nutrition replacement preparations

Dated this 10th day of October 2008.

ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate.

go7740

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Product: Bridion

  • Active Ingredient: Sugammadex 100mg/mL
  • Dosage Form: Solution for injection
  • New Zealand Sponsor: Pharmaco (NZ) Limited
  • Manufacturers:
    • NV Organon, Oss, The Netherlands
    • Organon (Ireland) Limited, Swords, Co. Dublin, Ireland

Product: Celsentri

  • Active Ingredient: Maraviroc 150mg
  • Dosage Form: Film coated tablet
  • New Zealand Sponsor: Pfizer New Zealand Limited
  • Manufacturer: Godecke GmbH, Freiburg, Germany

Product: Celsentri

  • Active Ingredient: Maraviroc 300mg
  • Dosage Form: Film coated tablet
  • New Zealand Sponsor: Pfizer New Zealand Limited
  • Manufacturer: Godecke GmbH, Freiburg, Germany

Product: Revlimid

  • Active Ingredient: Lenalidomide 10mg
  • Dosage Form: Capsule
  • New Zealand Sponsor: Celgene Pty Limited Quigg Partners
  • Manufacturers:
    • Norwich Pharmaceuticals Inc, Norwich, New York, United States of America
    • Penn Pharmaceutical Services Limited, Tredegar, Gwent, United Kingdom

Product: Revlimid

  • Active Ingredient: Lenalidomide 15mg
  • Dosage Form: Capsule
  • New Zealand Sponsor: Celgene Pty Limited Quigg Partners
  • Manufacturers:
    • Norwich Pharmaceuticals Inc, Norwich, New York, United States of America
    • Penn Pharmaceutical Services Limited, Tredegar, Gwent, United Kingdom

Product: Revlimid

  • Active Ingredient: Lenalidomide 25mg
  • Dosage Form: Capsule
  • New Zealand Sponsor: Celgene Pty Limited Quigg Partners
  • Manufacturers:
    • Norwich Pharmaceuticals Inc, Norwich, New York, United States of America
    • Penn Pharmaceutical Services Limited, Tredegar, Gwent, United Kingdom

Product: Revlimid

  • Active Ingredient: Lenalidomide 5mg
  • Dosage Form: Capsule
  • New Zealand Sponsor: Celgene Pty Limited Quigg Partners
  • Manufacturers:
    • Norwich Pharmaceuticals Inc, Norwich, New York, United States of America
    • Penn Pharmaceutical Services Limited, Tredegar, Gwent, United Kingdom


Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2008, No 159





✨ LLM interpretation of page content

🏥 Correction to Classification of Medicines

🏥 Health & Social Welfare
10 October 2008
Medicines Act 1981, Iron, Classification, Corrigendum
  • Anthony Hill, Deputy Director-General, Sector Accountability and Funding Directorate

🏥 Consent to Distribution of New Medicines

🏥 Health & Social Welfare
Medicines Act 1981, New Medicines, Distribution, Consent